As one of the most common diagnostic and therapeutic challenges, sepsis is the most significant cause of morbidity and mortality among newborns and older children. In addition to standard antibiotic treatment, numerous studies have been devoted to studying the clinical effectiveness of IgM-enriched immunoglobulins in treating sepsis. The aim of this study was to analyze children who were treated with IgM-enriched intravenous immunoglobulin [IgM-IVIG] as an adjunctive pharmacotherapy for sepsis in children, as well as the impact of the mentioned medicine on survival rate and hospitalization duration. A total of 20 children diagnosed with sepsis were treated at the Intensive Care Unit at the Pediatric Clinic of KBC Rijeka for five years from 01.01.2019 until 26.03.2024. All subjects received IgM-enriched immunoglobulins in therapy. Most patients were male (65%), while fifteen patients (75%) were born prematurely (gestational age 24-36 weeks). The average duration of hospitalization was 55.7 days. A total of 17 patients, among whom four children passed away, received IgM-enriched immunoglobulins for five days, and the average duration of their hospitalization was 61.5 days. The remaining three patients received immunoglobulins for three days, and their duration of hospitalization was 22.6 days. No adverse effects of this therapy were recorded in any case. Considering the relatively small number of subjects and the fact that the death of deceased patients occurred due to severe complications of prematurity, it is not possible to determine with certainty the influence of the length of receiving IgM-enriched immunoglobulin therapy on the length of hospitalization and mortality. Even though most current research suggests that IgM-enriched immunoglobulin therapy has shown to be a viable option for treating paediatric sepsis and septic shock, more research must be done on a more significant number of subjects so that the effects can be definitively proven.